FWM
SRNE

Focused Wealth Management’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Focused Wealth Management’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-6,000
Closed -$2.16K – 1137
2023
Q1 		$2.16K Hold
6,000
– – ﹤0.01% 789
2022
Q4 		$5.32K Sell
6,000
-8,000
-57% -$10.6K ﹤0.01% 630
2022
Q3 		$22K Hold
14,000
– – ﹤0.01% 385
2022
Q2 		$28K Hold
14,000
– – 0.01% 350
2022
Q1 		$33K Buy
14,000
+8,000
+133% +$25K 0.01% 358
2021
Q4 		$28K Sell
6,000
-5,500
-48% -$34.1K ﹤0.01% 445
2021
Q3 		$88K Buy
11,500
+1,500
+15% +$12.7K 0.01% 312
2021
Q2 		$97K Sell
10,000
-1,230
-11% -$9.79K 0.02% 295
2021
Q1 		$93K Sell
11,230
-1,000
-8% -$10.6K 0.02% 289
2020
Q4 		$83K Buy
12,230
+230
+2% +$1.85K 0.02% 294
2020
Q3 		$134K Hold
12,000
– – 0.03% 191
2020
Q2 		$75K Buy
12,000
+4,000
+50% +$15.3K 0.02% 262
2020
Q1 		$15K Buy
8,000
+6,500
+433% +$18.7K ﹤0.01% 415
2019
Q4 		$5K Buy
+1,500
New +$3.58K ﹤0.01% 585

Other funds holding SRNE

SW
SlateStone Wealth Jupiter, Florida $1.31B AUM 26.51% 1-Year Est. Return
KA
KLCM Advisors Milwaukee, Wisconsin $1.27B AUM 31.14% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return
AA
AlphaMark Advisors Ft. Wright, Kentucky $231M AUM 19.98% 1-Year Est. Return
OAJ
Ogorek Anthony Joseph Williamsville, New York $403M AUM 22.57% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
TCOV
Trust Company of Vermont Brattleboro, Vermont $2.68B AUM
CFGS
Concourse Financial Group Securities Birmingham, Alabama $1.77B AUM 17.37% 1-Year Est. Return

Focused Wealth Management's SRNE Position: Q2 2023 in Review

Focused Wealth Management sold out of Sorrento Therapeutics, Inc. (SRNE) in Q2 2023, closing a stake of 6,000 shares — an estimated $2.16K sold.

Focused Wealth Management first reported a position in SRNE in Q4 2019 and held it in 14 quarters. The position peaked at $134K in Q3 2020. 9 funds tracked by Wall St. Rank hold SRNE as of Q2 2023.

  • Focused Wealth Management reported no remaining Sorrento Therapeutics, Inc. position as of Q2 2023 after selling out during the quarter.
  • Focused Wealth Management sold 6,000 Sorrento Therapeutics, Inc. shares in Q2 2023, an estimated $2.16K.
  • Focused Wealth Management first reported a position in Sorrento Therapeutics, Inc. in Q4 2019 and held it in 14 quarters.
  • Focused Wealth Management's Sorrento Therapeutics, Inc. position peaked at $134K in Q3 2020.
  • 9 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q2 2023.

Based on Focused Wealth Management's 13F filing for Q2 2023, filed 8 Aug 2023.